TrialLancet (London, England)2012

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study.

Robert P Giugliano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.